LOGIN  |  REGISTER
Chimerix
Assertio

Solventum to Report Third Quarter Fiscal 2025 Earnings on November 6, 2025

October 16, 2025 | Last Trade: US$80.68 0.73 0.91

ST. PAUL, Minn., Oct. 16, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its third quarter fiscal 2025 financial results on Thursday, Nov. 6, 2025, after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast.

Earnings webcast details:

Date:

Thursday, Nov. 6, 2025

Time:

3:30 p.m. CST / 4:30 p.m. EST

Location:

https://investors.solventum.com

U.S. dial-in

+1 (800) 715-9871

International dial-in:

+1 (646) 307-1963

Conference ID:

6342275

A replay of the webcast, the earnings press release, presentation slides, and supplemental financial disclosures will be available on the Investor Relations section of Solventum's website.

About Solventum

At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com

Assertio

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page